High-value-added products and services that contribute to reducing patients’ financial burden, improving medical safety, and enhancing operational efficiency
First written in FY2016. 11 of 22 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「① Introduced at 986 facilities globally (927 in Japan and 59 overseas, with operations expanded to 8 overseas countries) ② Introduced at 31% of designated cancer hospitals in Japan. ③ Used by approximately 15,000 patients globally.」
For solutions aimed at reducing the burden on patients and healthcare professionals, improving medical safety, and enhancing operational efficiency, implementation and use expanded to 986 facilities for perioperative solutions, 31% of designated cancer hospitals in Japan for outpatient chemotherapy solutions, and approximately 15,000 people for renal care. - FY2025AdvancedAnnual report
「Introduced at 836 facilities globally (785 in Japan and 51 overseas, with operations expanded to 8 overseas countries)」
For solutions aimed at reducing the burden on patients and healthcare professionals and improving medical safety, perioperative solutions were introduced at 836 facilities globally. Outpatient chemotherapy solutions were introduced at 30% of designated cancer hospitals in Japan, and renal care solutions were used by approximately 12,000 people globally. - FY2024AdvancedAnnual report
「② ChemoSafe Lock, a closed-system drug-transfer device, has been introduced at more than 30% of designated cancer hospitals in Japan, and multiple medical institutions have submitted budget requests for the introduction of a medication-management support system for outpatient chemotherapy.」
The company disclosed the implementation record for ChemoSafe Lock and preparations for introducing a medication-management support system as solutions aimed at reducing the burden on patients and healthcare professionals and improving medical safety. - FY2023AdvancedAnnual report
「The vision of Medical Care Solutions Company is to “contribute to improving and transforming healthcare through patient-centered solutions that combine our proprietary technologies.” To achieve this vision, the company will implement the following 4 strategies.」
The company gave concrete form to its former policy on high-value-added products and services through 4 solution strategies: hospital care, life care, pharmaceuticals, and overseas business. - FY2022AdvancedAnnual report
「The vision for the 5-year growth strategy is to “contribute to improving and transforming healthcare through patient-centered solutions that combine our proprietary technologies.”」
The company gave concrete form to its former policy on high-value-added products and services through patient-centered solutions combining medical devices, data, medical safety, and hospital management efficiency. - FY2022-Q3AdvancedAnnual report
「In the Hospital Systems Business, sales of infusion pumps and syringe pumps remained strong in both Japan and overseas as healthcare demand recovered and healthcare systems were further strengthened. Alliance business also continued to expand. Global revenue was ¥138.7 billion, up 7.5% year on year.」
Hospital Company revenue increased 7.5% year on year, driven by the expansion of infusion pumps, syringe pumps, and alliance business, which provide high-value-added products and services for healthcare settings. - FY2021AdvancedAnnual report
「Supported by infection-control products and anesthetic analgesics in the Hospital Systems Business in Japan, as well as the global expansion of alliance business with pharmaceutical companies, Hospital Company's revenue was ¥175.5 billion, up 2.7% year on year.」
Hospital Company achieved full-year revenue growth, driven by infection-control products, anesthetic analgesics, and alliance business with pharmaceutical companies. - FY2021-Q3Recovery in Hospital Business revenueAnnual report
「Although many products in Japan were affected by the spread of COVID-19, sales of infection-control products and anesthetic analgesics in the Hospital Systems Business provided support. In addition, alliance business with pharmaceutical companies expanded globally. As a result, Hospital Company's revenue was ¥129.0 billion, up 1.0% year on year.」
Hospital Company revenue increased 1.0% year on year, supported by infection-control products, anesthetic analgesics, and alliance business with pharmaceutical companies. - FY2021-Q1Responding to product demand during the spread of infectious diseasesAnnual report
「Although many products in Japan were affected by the spread of COVID-19, sales of anesthetic analgesics, thermometers, ultraviolet irradiation robots, and hand sanitizers in the Hospital Systems Business provided support. In addition, alliance business with pharmaceutical companies expanded overseas. As a result, Hospital Company's revenue was ¥39.2 billion, down 1.4% year on year.」
Although the spread of infectious diseases affected many products, increased demand for thermometers, ultraviolet irradiation robots, hand sanitizers, and other products, together with the expansion of alliance business with pharmaceutical companies, supported the Hospital Business. - FY2020AdvancedAnnual report
「As COVID-19 continued to have a major impact on society worldwide, Hospital Company further expanded the infection-control initiatives it had pursued for many years.」
The company gave concrete form to its established policy of prioritizing patient and healthcare-setting safety by expanding infection-control measures during the COVID-19 pandemic, digitizing drug administration, and improving the quality and efficiency of healthcare. - FY2020-Q3RestatedAnnual report
「In the Hospital field, demand is increasing for safety measures to prevent medical accidents and infections, as well as for administration systems suited to pharmaceutical innovation.」
The company continues to indicate that it views demand for preventing medical accidents and infections, and for drug administration systems, as growth opportunities and will provide high-value-added products and services that meet the needs of healthcare settings. - FY2020-Q2RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of viewing emerging market needs as growth opportunities and driving innovation through product development that meets the needs of healthcare settings. - FY2019RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of pursuing sustainable, profitable growth through product development that meets the needs of healthcare settings and through innovation. - FY2019-Q3RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of viewing emerging market needs as growth opportunities and driving innovation through product development that meets the needs of healthcare settings. - FY2019-Q2RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of viewing emerging market needs as growth opportunities and driving innovation through product development that meets the needs of healthcare settings. - FY2018-Q3RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of viewing emerging market needs as growth opportunities and driving innovation through product development that meets the needs of healthcare settings. - FY2018-Q2RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of pursuing growth through product development that meets the needs of healthcare settings and through innovation. - FY2018-Q1RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of pursuing growth through product development that meets the needs of healthcare settings and through innovation. - FY2017-Q3RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company continues to describe its policy of pursuing growth through product development that meets the needs of healthcare settings and through innovation. - FY2017-Q2RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company is reaffirming its policy of pursuing growth through product development that meets the needs of healthcare settings and through innovation. - FY2017-Q1RestatedAnnual report
「By viewing these emerging market needs as growth opportunities, the company aims to contribute to society through healthcare, its corporate philosophy, and to achieve sustainable and profitable growth. At the same time, it will drive innovation through product development that meets the needs of healthcare settings and strive to become a company with a strong presence worldwide.」
The company is reiterating its policy of pursuing growth through product development that meets the needs of healthcare settings and through innovation. - FY2016First statedAnnual report
「The company will continue to provide globally high-value-added products and services that help reduce patient burden, improve safety in healthcare settings, and enhance operational efficiency.」
The company identifies minimally invasive treatment, safety, and operational efficiency as specific areas for adding value.